AI and machine learning will be increasingly used in the health care industry as it "de-risks" to overcome regulatory barriers, according to Cardiologs CEO FleureauYann Fleureau. The past two years have seen companies validate diagnostics software and other programmes that demonstrate the technology's effectiveness, said Yann Fleureau. As such, he expects next year to be a time of commercial and clinical validation, showing that such emerging solutions will be able to effectively manage patients.
AI and machine learning will be increasingly used in the health care industry as it "de-risks" to overcome regulatory barriers, according to Cardiologs CEO Yann Fleureau. The past two years have seen companies validate diagnostics software and other programmes that demonstrate the technology's effectiveness, said Fleureau. As such, he expects next year to be a time of commercial and clinical validation, showing that such emerging solutions will be able to effectively manage patients.